Cargando…
Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increa...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060048/ https://www.ncbi.nlm.nih.gov/pubmed/30994503 http://dx.doi.org/10.1097/COH.0000000000000549 |
_version_ | 1783504156424667136 |
---|---|
author | Brouwer, Philip J.M. Sanders, Rogier W. |
author_facet | Brouwer, Philip J.M. Sanders, Rogier W. |
author_sort | Brouwer, Philip J.M. |
collection | PubMed |
description | PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increase Env immunogenicity. Recent studies have shed light on how Env nanoparticles increase lymph node trafficking and germinal center formation by using the lectin-mediated complement pathway and enhancing the interaction with naïve B cells. Meanwhile, research on different nanoparticle platforms has resulted in improved designs, such as liposomes with improved stability, and the emergence of novel platforms such as protein nanoparticles that self-assemble in vitro. Immmunogenicity studies with these nanoparticles delineate the advantages and expose the limitations of the different nanoparticle platforms. SUMMARY: It is becoming increasingly clear that HIV-1 vaccine research might benefit greatly from using nanoparticles presenting Env trimers, particularly during the priming stage of immunization. Among the different nanoparticles that are being pursued, in vitro-assembling nanoparticles allow for greater control of Env quality making them a promising nanoparticle platform. |
format | Online Article Text |
id | pubmed-7060048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-70600482020-03-19 Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms Brouwer, Philip J.M. Sanders, Rogier W. Curr Opin HIV AIDS BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz PURPOSE OF REVIEW: We will discuss recent advances in the development of nanoparticle vaccines presenting HIV-1 envelope trimer vaccines and the immunological mechanisms by which they act. RECENT FINDINGS: The multivalent presentation of Env trimers on nanoparticles is a promising strategy to increase Env immunogenicity. Recent studies have shed light on how Env nanoparticles increase lymph node trafficking and germinal center formation by using the lectin-mediated complement pathway and enhancing the interaction with naïve B cells. Meanwhile, research on different nanoparticle platforms has resulted in improved designs, such as liposomes with improved stability, and the emergence of novel platforms such as protein nanoparticles that self-assemble in vitro. Immmunogenicity studies with these nanoparticles delineate the advantages and expose the limitations of the different nanoparticle platforms. SUMMARY: It is becoming increasingly clear that HIV-1 vaccine research might benefit greatly from using nanoparticles presenting Env trimers, particularly during the priming stage of immunization. Among the different nanoparticles that are being pursued, in vitro-assembling nanoparticles allow for greater control of Env quality making them a promising nanoparticle platform. Lippincott Williams & Wilkins 2019-07 2019-02-25 /pmc/articles/PMC7060048/ /pubmed/30994503 http://dx.doi.org/10.1097/COH.0000000000000549 Text en Copyright © 2019 Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz Brouwer, Philip J.M. Sanders, Rogier W. Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
title | Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
title_full | Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
title_fullStr | Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
title_full_unstemmed | Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
title_short | Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
title_sort | presentation of hiv-1 envelope glycoprotein trimers on diverse nanoparticle platforms |
topic | BROAD NEUTRALISING AND NON-NEUTRALISING ANTIBODIES: Edited by Hugo Mouquet and Olivier Schwartz |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060048/ https://www.ncbi.nlm.nih.gov/pubmed/30994503 http://dx.doi.org/10.1097/COH.0000000000000549 |
work_keys_str_mv | AT brouwerphilipjm presentationofhiv1envelopeglycoproteintrimersondiversenanoparticleplatforms AT sandersrogierw presentationofhiv1envelopeglycoproteintrimersondiversenanoparticleplatforms |